Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Opportunistic infections: an update.

Hansjakob Furrer1, Christoph Fux

  • 1Division of Infectious Diseases, University Hospital, Inselspital PKT2 B, CH 3010 Bern, Switzerland. hansjakob.furrer@insel.ch

Journal of HIV Therapy
|April 17, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effect of implementing measures to reduce resource utilisation in medical wards (CopAIN project): a single-centre interrupted time-series analysis.

Swiss medical weekly·2026
Same author

Association of a polygenic risk score with low trauma fractures in people with HIV - The swiss HIV cohort study.

PloS one·2026
Same author

Hemophagocytic Syndromes in Adults: Real-World Data on Mortality from a Tertiary Reference Center.

Acta haematologica·2025
Same author

Machine Learning-based Prediction of Active Tuberculosis in People With HIV Using Clinical Data.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2025
Same author

Population pharmacokinetics of rilpivirine following oral administration and long-acting intramuscular injection in real-world people with HIV.

Frontiers in pharmacology·2024
Same author

HIV-1 Low-Level Viremia Predicts Viral Failure in Participants on Antiretroviral Therapy in the Swiss HIV Cohort Study.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2024
Same journal

Implications of the SILCAAT and ESPRIT trials and the future for HIV immunotherapy.

Journal of HIV therapy·2010
Same journal

A review of the use of activation markers in Africa.

Journal of HIV therapy·2010
Same journal

Lymphocyte activation in HIV-1 infection: time for quality control.

Journal of HIV therapy·2010
Same journal

HIV immunology: what lessons can we learn from recent vaccine trials?

Journal of HIV therapy·2010
Same journal

SILCAAT and ESPRIT: taking stock.

Journal of HIV therapy·2010
Same journal

HIV, atherosclerosis and inflammation: implications for treatment.

Journal of HIV therapy·2010
See all related articles

Highly active antiretroviral therapy (HAART) improves survival and reduces opportunistic infections (OIs). However, early mycobacterial and CMV diseases persist, necessitating updated prophylaxis guidelines for HAART patients.

Area of Science:

  • Infectious Diseases
  • Immunology
  • Public Health

Background:

  • Highly active antiretroviral therapy (HAART) has significantly improved outcomes for individuals with HIV/AIDS.
  • Despite HAART, opportunistic infections (OIs) like mycobacterial diseases and cytomegalovirus (CMV) disease remain a concern in the initial treatment period.

Purpose of the Study:

  • To evaluate the impact of HAART on the incidence and risk factors of OIs.
  • To assess the utility of CD4 count as a marker for OI risk in HAART-treated patients.
  • To provide evidence-based recommendations for revising OI prophylaxis and maintenance therapy.

Main Methods:

  • Analysis of clinical data from HAART-treated patients.
  • Monitoring of opportunistic infection incidence and CD4 counts over time.

Related Experiment Videos

  • Review of immunopathogenic mechanisms related to immune reconstitution.

    • Main Results:

    • HAART has led to a decline in overall OI incidence and improved survival post-AIDS diagnosis.
    • Mycobacterial and CMV disease rates are elevated in the first 3 months of HAART.
    • A CD4 count of 200 cells/μL after 6 months of HAART predicts a low subsequent risk of OIs.

    Conclusions:

    • Current OI prophylaxis and maintenance therapy guidelines require re-evaluation in light of HAART's effectiveness.
    • Discontinuing primary prophylaxis for Pneumocystis carinii pneumonia, toxoplasma encephalitis, and Mycobacterium avium infection is supported by strong evidence.
    • Understanding immune reconstitution is key to managing OIs in the HAART era.